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Abstract
Introduction. Patients with type 2 diabetes and hypertension are at a significantly increased risk of cardiovascular mor-
tality, including due to myocardial infarction, and often suffer from other diseases and cardiovascular complications.
Material and methods. We studied 2513 hospitalised patients with hypertension who were divided into two groups: 
with diabetes (DM+, n = 637) and without diabetes DM–, n = 1876). The two groups were compared in regard to age, 
gender, and selected concomitant diseases and cardiovascular complications.
Results. Mean age was 70 ± 9.7 years in the DM+ group vs. 68 ± 11.0 years in the DM– group (p = 0.0001), with 51.2% 
women in the DM+ group compared to 43.4% women in the DM– group (p = 0.0004). The following conditions were more 
frequent in the DM+ group compared to the DM– group: heart failure (43.8% vs. 35.5%, p = 0.0001), atrial fibrillation 
(34.8% vs. 24.7%, p = 0.03), stroke (6.6% vs. 4.4%, p = 0.03), hypertriglyceridaemia (153 ± 72.1 vs. 37.1 ± 74.4 mg/dL, 
p = 0.0004), low HDL cholesterol level (43.4 ± 14.6 vs. 46.9 ± 19.7 mg/dL, p = 0.0002), and reduced glomerular filtration 
rate (51.42 ± 19.82 vs. 56.94 ± 16.08 mL/min/1.73 m2 (p = 0.0001). No differences were found in regard to the rates 
of stable coronary artery disease (33.7% vs. 29.3%, p = NS) and left ventricular hypertrophy (34.8% vs. 30.7%, p = NS).
Conclusions
1.  Diabetes was significantly more common among hypertensive women compared to hypertensive men. Patients with 
diabetes were significantly older.
2. Macroangiopathic complications (previous myocardial infarction or stroke) and concomitant diseases (atrial fibrilla-
tion, heart failure, nephropathy) were significantly more frequent in patients with diabetes.
3. Stable coronary artery disease and left ventricular hypertrophy occurred at a similar rate in patients with or without 
diabetes.
4. Atherogenic dyslipidaemia was more frequent among patients with diabetes.
Key words: diabetes, hypertension, myocardial infarction, heart failure, left ventricular hypertrophy
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Introduction
Type 2 diabetes is a major cardiovascular risk factor. In the 
European Society of Cardiology guidelines, diabetes was 
considered a coronary heart disease risk equivalent, indi-
cating a very high cardiovascular risk in these patients [1]. 
Multiple studies show that the risk of myocardial infarction 
and cardiovascular mortality among diabetes patients 
without established coronary heart disease is similar to 
the risk among non-diabetic patients after a myocardial 
infarction. It has been estimated that in diabetic patients, 
coronary heart disease manifests on average 15 years 
earlier than in non-diabetic subjects [2].
Compared to patients without diabetes, diabetic pa-
tients are usually older, with a higher proportion of women 
and higher rates of obesity, hypertension, previous myocar-
dial infarction, heart failure, and previous revascularisation 
procedures [3].
The rate of hypertension accompanying type 2 diabe-
tes is increased up to three-fold compared to the general 
population [1]. Concomitant occurrence of hypertension 
and diabetes, with its complex underlying pathogenetic 
mechanisms, is associated with a significantly increased 
risk of cardiovascular mortality, including due to myocardial 
infarction [4].
Material and methods
We retrospectively analysed 2513 patients with hyperten-
sion hospitalised in a cardiology department in 2009– 
–2010. The study group (DM+) included 637 patients 
with hypertension and concomitant diabetes (25.3% of 
the overall study population), and the control group (DM–) 
included 1876 with hypertension and no concomitant dia-
betes (74.7%). The proportion of men among all patients 
was 54.6% (n = 1372), and 22.6% of them had diabetes, 
and for women these figures were 45.4% (n = 1140) and 
28.6%, respectively. The two groups were compared in 
regard to the rates of selected concomitant diseases and 
cardiovascular complications.
The diagnosis of hypertension was based on history 
(including a history of antihypertensive drug use) and 
physical examination findings — the mean of at least two 
blood pressure measurements on at least two days of ho-
spital stay ≥ 140 mm Hg for systolic blood pressure and/or 
≥ 90 mm Hg for diastolic blood pressure. The diagnosis of 
diabetes was based on three complementary criteria: fas-
ting blood glucose level > 125 mg/dL (two measurements 
on two consecutive days of hospital stay), random blood 
glucose level ≥ 200 mg/dL with clinical signs of hypergly-
caemia, and a positive oral glucose tolerance test (blood 
glucose level 2 hours after oral administration of 75 g of 
glucose ≥ 200 mg/dL). Heart failure was diagnosed based on 
typical symptoms and signs. Ischaemic heart disease was 
diagnosed based on a history of typical symptoms and/or 
pre vious myocardial infarction. Dyslipidaemia was defined as 
the following lipid levels: total cholesterol ≥ 190 mg/dL, 
low-density lipoprotein (LDL) cholesterol ≥ 115 mg/dL, 
high-density lipoprotein (HDL) cholesterol ≤ 40 mg/dL, and 
triglycerides ≥ 150 mg/dL, or a history of lipid-lowering 
drug use. Left ventricular ejection fraction was evaluated 
by echocardiography using the Simpson method or by 
visual assessment, and left ventricular hypertrophy was 
defined as interventricular septum thickness of ≥ 12 mm. 
Atrial fibrillation was diagnosed based on a history of 
arrhythmia and/or electrocardiographic findings. Renal 
dysfunction was evaluated based on glomerular filtration 
rare as estimated using the Modification of Diet in Renal 
Disease (MDRD) formula.
Statistical analysis was performed using a licensed 
copy of the STATISTICA 10 package. For each variable, the 
arithmetic mean with standard deviation was calculated. 
Normal distribution of the variables was evaluated using 
the Shapiro-Wilk test. Significance of differences in the 
mean values of normally distributed variables was evalua-
ted using the Student t test for unpaired samples, and the 
Mann-Whitney U test was used for non-normally distributed 
variables. For these comparisons, p < 0.05 was considered 
statistically significant.
Results
The mean age was 70 ± 9.7 years in the DM+ group com-
pared to 68 ± 11.0 years in the DM– group, a statistically 
significant difference (p = 0.0001). The proportion of wo-
men was 51.2% (326/637) in the DM+ group compared 
to 43.4% (814/1876) in the DM– group, again a statisti-
cally significant difference (p = 0.0004). Diabetes was 
significantly more frequent among women compared to 
men (326/1140 [28.6%] vs. 310/1372 [22.6%] patients, 
respectively, p = 0.001). Insulin therapy was used in 138 
patients in the DM+ group (21.7%), and the remaining pa-
tients (n = 497, 78.0%) received oral hypoglycaemic agents.
Previous myocardial infarction was reported in 78 
patients (12.3%) in the DM+ group compared to 155 
patients (8.3%) in the DM– group (p = 0.002). The rate of 
stable coronary artery disease did not differ between the 
groups (214/637 [33.7%] vs. 550/1876 [29.3%] patients, 
respectively, p = NS).
Heart failure was significantly more common in the 
DM+ group (278 patients [43.8%] compared to 667 pa-
tients [35.5%] in the DM– group, p = 0.0001) (Table 1). 
When we analysed the severity of heart failure in the DM+ 
and DM– groups as assessed using the New York Heart 
Association (NYHA) classification, 129 (20.3%) vs. 337 
(18.0%) patients were in NYHA class II, respectively, 118 
(18.5%) vs. 277 (12.3%) patients were in NYHA class III, 
and 31 (4.9%) vs. 53 (2.8%) patients were in NYHA class 
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IV (Figure 1). Left ventricular ejection fraction was signifi-
cantly lower in the DM+ group compared to the DM– group 
(46% ± 13% vs. 50% ± 16%, p = 0.0001). The rate of left 
ventricular hypertrophy did not differ between the DM+ 
and DM– groups (221 [34.8%] vs. 577 [30.7%] patients, 
respectively, p = NS).
Atrial fibrillation was significantly more frequent in the 
DM+ group compared to the DM– group (221 [34.8%] 
vs. 464 [24.7%] patients, respectively, p = 0.03), as was 
previous stroke (42 [6.6%] vs. 84 [4.4%] patients, respec-
tively, p = 0.03).
Compared to the DM– group, dyslipidaemia was signif-
icantly more frequent in the DM+ group, including hypertri-
glyceridaemia (153 ± 72.1 mg/dL vs. 37.1 ± 74.4 mg/dL, 
respectively, p = 0.0004) and low HDL cholesterol level 
(43.4 ± 14.6 mg/dL vs. 46.9 ± 19.7 mg/dL, p = 0.0002) 
(Figure 2).
Glomerular filtration rate estimated using the MDRD 
formula was significantly lower in the DM+ group compared 
to the DM– group (51.42 ± 19.82 vs. 56.94 ± 16.08 mL/ 
/min/1.73 m2, respectively, p = 0.0001).
A summary of these findings is shown in Table 1.
Discussion
In our study, diabetes was present in 24.5% of hospitalised 
patients, significantly more frequently among women com-
pared to men. The proportion of women was higher among 
diabetic patients than among those with normal glucose 
tolerance (51% vs. 43%, respectively).
The mean age was 70 years in the diabetic group com-
pared to 68 years in the non-diabetic group. It has been 
noted that the prevalence of diabetes increases with age 
until about 70-75 years of age and then decreases, likely 
due to premature mortality related to diabetes complica-
tions [5]. Based on a 7-year follow-up study by Haffner et 
al. who showed that the incidence of myocardial infarction 
among patients with diabetes was similar to that among 
non-diabetic patients after myocardial infarction [6], 
Table 1. Rates of selected comorbidities and complications in the DM+ and DM– groups





Age (years) 70 ± 9.7 68 ± 11.4 0.0001
Gender (women/men) 326 (51.3%)/309 (48.7%) 813 (43.4%)/1063 (56.7%) 0.0004
Previous myocardial infarction 78 (12.3%) 155 (8.3%) 0.002
Ischaemic heart disease 214 (33.7%) 550 (29.3%) NS
Heart failure 278 (43.8%) 667 (35.5%) 0.0001
Atrial fibrillation 221 (34.8%) 464 (24.7%) 0.03
Previous stroke 42 (6.6%) 84 (4.4%) 0.03
Total cholesterol [mg/dL] 170 ± 71.5 179 ± 49.0 0.0002
LDL cholesterol [mg/dL] 101 ± 44.5 107.9 ± 42.9 0.001
HDL cholesterol [mg/dL] 43.4 ± 14.6 46.9 ± 19.7 0.0002
Triglycerides [mg/dL] 153 ± 72.4 137.1 ± 74.4 0.0004
eGFR [mL/min/1.73 m2] 51.42 ± 19.82 56.94 ± 16.08 0.0001
Blood glucose [mg/dL] 150 ± 66.83 100 ± 39.3 0.0001
Left ventricular ejection fraction (%) 46 ± 13 50 ± 16 0.0001
Left ventricular hypertrophy [mm] 221 (34.8%) 577 (30.7%) NS
DM — diabetes mellitus; NS — not significant
Figure 1. Heart failure severity in the DM+ and DM– groups as 
assessed using the New York Heart Association classification; 
DM — diabetes mellitus
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diabetes was considered a coronary heart disease risk 
equivalent [7].
Multiple studies showed that cardiovascular disease in 
diabetic patients is significantly more frequent and occurs 
much earlier compared to patients without diabetes. In 
the Framingham Heart Study population, the rate of car-
diovascular disease was increased 2-fold in diabetic men 
and 3-fold in diabetic women [8]. One study showed that 
on average, the presence of diabetes was associated with 
a 15-fold increase in cardiovascular risk [2]. In addition, 
cardiovascular complications often precede the diagnosis 
of diabetes. In the study by Kowalska et al. among men with 
stable ischaemic heart disease with no prior diagnosis of 
diabetes, in whom coronary atherosclerotic lesions were 
confirmed by angiography, abnormal glucose tolerance was 
identified by oral glucose tolerance test in more than 50% 
of patients (including type 2 diabetes in 16% of patients, 
and impaired glucose tolerance in 36% of patients) [9]. 
An increased rate of myocardial infarction in patients with 
diabetes was confirmed by Haffner et al. who showed that 
during a 7-year follow-up, the risk of myocardial infarction 
in diabetic patients was significantly increased in patients 
with a history of myocardial infarction compared to those 
with no previous infarction (45% vs. 20.2%), while these 
rates in non-diabetic patients were 18.8% vs. 3.5%, respec-
tively (p < 0.001) [6]. Also in the Framingham Heart Study, 
recurrent myocardial infarction in diabetic patients was fou-
nd to occur more frequently and earlier, particularly among 
women [10]. In our study, previous myocardial infarction 
was noted in 12% of diabetic patients compared to 8% of 
patients without diabetes. Stable ischaemic heart disease 
was noted in 34% vs. 29% of these patients, respectively, 
with no significant differences between the two groups.
In our study, the rate of atrial fibrillation was higher 
among patients with diabetes (221/637, 34.8%) compared 
to those without diabetes (464/1876, 24.7%). In previou-
sly published reports, diabetes was found in 7.6–13% of 
patients with atrial fibrillation. Nichols et al. reported that 
atrial fibrillation was significantly more frequent in patients 
with established diabetes compared to those without 
diabetes [11]. Much data on the coexistence of atrial fibril-
lation and diabetes were provided by the Atherosclerosis 
Risk in Communities (ARIC) study. Compared to patients 
without diabetes, the risk of incident atrial fibrillation was 
increased by 1/3 in patients with diabetes. A significant 
association was shown between fasting blood glucose and 
glycated haemoglobin levels in diabetic patients and the 
occurrence of atrial fibrillation. Diabetes was identified as 
an independent risk factor for atrial fibrillation in some, but 
not all studies [12]. Thus, identification of atrial fibrillation 
has not been a priority in patients with diabetes due to 
more frequent occurrence of asymptomatic arrhythmia. In 
addition, the European Society of Cardiology recommends 
looking for atrial fibrillation by taking pulse, and recording 
an electrocardiogram whenever irregular heart rate is iden-
tified, in all patients aged ≥ 65 years seen by primary care 
physicians [13]. Presence of diabetes is associated with 
worse outcomes of atrial fibrillation due to an increased 
risk of all-cause mortality, increased cardiovascular morta-
lity, and an increased risk of heart failure and particularly 
Figure 2. Lipid profile in the DM+ and DM– groups; DM — diabetes mellitus; LDL — low-density lipoprotein; HDL — high-density lipoprotein
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ischaemic stroke. In our study, stroke was more frequent 
in the diabetic compared to the non-diabetic group, as 
diabetes is a risk factor for thromboembolic complications 
in this patient population.
Diabetic patients are characterized by an increased 
incidence of heart failure. This is largely related to the 
development of atherosclerosis related to diabetes, but dia-
betic cardiomyopathy resulting from impaired cardiomyo-
cyte metabolism also plays a role [14]. Diabetes impairs 
both systolic and diastolic function of the left ventricle due 
to myocardial fibrosis and ischemia. A relation between 
diabetes and heart failure was first identified in the Fra-
mingham Heart study [15]. In the overall study population 
(aged 45–74 years), diabetes was associated with a 2-fold 
increased risk of heart failure in men and a 5-fold increased 
risk in women, and in younger subjects (< 65 years) this 
risk was increased as much as 8-fold in women and 4-fold 
in men compared to subjects without diabetes [15]. The 
rate of heart failure among diabetic patients is up to 22%, 
and the incidence has been estimated at 0.4–13% per 
year [16]. On the other hand, the rate of diabetes among 
patients with heart failure is 20–30%, and thus it is much 
increased compared to the general population [17]. In our 
study, the rate of heart failure in hospitalised patients with 
diabetes and hypertension was 43.8% (278/637) compa-
red to 35.5% (667/2876) among those without diabetes. 
Left ventricular ejection fraction was also significantly 
lower in patients with diabetes (46% vs. 50%, respecti-
vely; p = 0.0001). Risk factors for heart failure in diabetes 
include symptomatic coronary artery disease, age, female 
gender, obesity, hypertension, long duration of diabetes, 
hyperglycaemia, and microangiopathy. The incidence of 
heart failure is twice increased among diabetic patients 
with a history of coronary artery disease compared to 
those without coronary artery disease. Only one third of 
heart failure cases develop in subjects without previously 
established coronary artery disease [16].
The prevalence of left ventricular hypertrophy in diabetic 
patients is increased independently from the occurrence of 
the major cause of hypertrophy, i.e. arterial hypertension. 
In the Strong Heart Study, left ventricular hypertrophy was 
identified in 19% of diabetic patients without concomitant 
hypertension and in 38% of patients with diabetes and 
hypertension [18]. In our study, left ventricular hypertrophy 
was present in 35% of patients with diabetes and hyper-
tension compared to 31% of patients without diabetes. 
Diabetes, hypertension, and obesity are all independent 
risk factors for left ventricular hypertrophy [19].
The atherogenic dyslipidaemia of diabetes, characte-
rised by elevated triglycerides, low HDL cholesterol level, 
and increased levels of small dense LDL, apolipoprotein 
B, and very low-density lipoproteins (VLDL), initiates and 
promotes progression of atherosclerosis, leading to an 
increase in cardiovascular risk [20]. Elevated triglyceride 
level is the major lipid abnormality in diabetes. In addition, 
triglyceride-rich lipoproteins are elevated, both originating 
from the small intestine (chylomicrons) and endogenously 
synthesized (VLDL), leading to increased and prolonged 
postprandial hyperlipaemia. This results in an increased 
exposure of the vessel wall to the atherogenic effect of 
these lipoproteins. In our study group with hypertension 
and diabetes, a significantly higher triglyceride level was 
found compared to the study group, along with a signifi-
cantly lower HDL cholesterol level, which confirmed the 
presence of an atherogenic lipid profile in patients with 
diabetes. At the same time, we found significantly lower 
levels of total cholesterol and LDL cholesterol compared 
to the control group, which is consistent with the literature 
data indicating that no significant hypercholesterolemia is 
usually present in patients with diabetes [20]. This was 
also likely related to appropriate lipid-lowering treatment in 
those patients with diabetes and hypertension. An elevated 
total cholesterol level may result from poorly controlled 
diabetes. LDL cholesterol level was only slightly elevated, 
thus not reflecting the actual cardiovascular risk related to 
dyslipidaemia that accompanies diabetes [20]. Although 
LDL cholesterol level is not significantly increased, each 
LDL particle carries a larger load of apolipoprotein B in 
diabetic than in non-diabetic patients.
Nephropathy is also an important factor affecting 
cardiovascular risk in patients with diabetes and hyper-
tension. At the time when type 2 diabetes is diagnosed, 
microalbuminuria is present in 19% of patients, and overt 
proteinuria in 5% of patients. Diabetic nephropathy is 
associated with an increased mortality risk and increased 
rates of cardiovascular complications [21]. In our study, 
mean glomerular filtration rate was significantly lower in 
diabetic than in non-diabetic patients.
Study limitations
The major limitation of our study was a sample size 
disproportion between the groups with or without diabe-
tes, with a much larger control group without diabetes. 
Our findings indicate, however, a strong predilection for 
cardiovascular complications among those fewer patients 
with diabetes. It is even more important due to the fact 
that the overall study population was quite large (more 
than 2500 subjects), increasing the statistical power 
of our results. Another limitation was the fact that we 
performed a single-centre, retrospective analysis of the 
prevalence of selected conditions depending on the 
presence of diabetes, without a prospective attempt to 
follow-up progression of these disturbances in relation to 
diabetes duration and control.
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Conclusions
1. Diabetes was significantly more common among hy-
pertensive women compared to hypertensive men. 
Patients with diabetes were significantly older than 
those without diabetes.
2. Macroangiopathic complications including previous 
myocardial infarction and stroke and concomitant 
diseases such as atrial fibrillation, heart failure, and 
nephropathy were significantly more frequent in hyper-
tensive patients with diabetes than in those without 
concomitant diabetes.
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Wstęp. Chorych na cukrzycę typu 2 z nadciśnieniem tętniczym cechuje istotnie podwyższone ryzyko zgonu z przyczyn 
sercowo-naczyniowych, w tym zawału serca, oraz często zapadają na inne choroby i powikłania sercowo-naczyniowe.
Materiały i metody. Analizą objęto 2513 hospitalizowanych chorych z nadciśnieniem tętniczym, których podzielono na 
dwie grupy: z cukrzycą (DM+) — 637 chorych i bez cukrzycy (DM–) — 1876 chorych. Grupy porównano pod względem 
wieku, płci oraz współwystępowania wybranych chorób i powikłań sercowo-naczyniowych.
Wyniki. Średnia wieku w grupie DM+ wynosiła 70 ± 9,7 roku, a w grupie DM– 68 ± 11,0 lat (p = 0,0001). W grupie DM+ 
kobiety stanowiły 51,2%, natomiast w grupie DM– 43,4% (p = 0,0004). W grupie DM+ częściej niż w grupie DM– wystę-
powały: niewydolność serca (43,8 v. 35,5%; p = 0,0001), migotanie przedsionków (34,8 v. 24,7%; p = 0,03), udar mózgu 
(6,6 v. 4,4%; p = 0,03), hipertriglicerydemia (153 ± 72,1 mg/dl v. 37,1 ± 74,4 mg/dl; p = 0,0004), obniżone stężenie 
cholesterolu frakcji HDL (43,4 ± 14,6 mg/dl v. 46,9 ± 19,7 mg/dl; p = 0,0002), obniżony wskaźnik filtracji kłębuszkowej 
(51,42 ± 19,82 v. 56,94 ± 16,08 ml/min/1,73 m2; p = 0,0001). Nie wykazano różnic w zakresie współwystępowania 
stabilnej choroby wieńcowej (33,7 v. 29,3%; p = NS) i przerostu lewej komory (34,8 v. 30,7%, p = NS).
Wnioski
1 Cukrzyca występowała istotnie częściej u kobiet niż u mężczyzn z nadciśnieniem tętniczym. Chorzy na cukrzycę byli 
istotnie starsi.
2 Powikłania makroangiopatyczne (przebyty zawał serca i udar mózgu) i choroby towarzyszące (migotanie przedsion-
ków, niewydolność serca, nefropatia) występowały istotnie częściej u chorych na cukrzycę.
3 Stabilna choroba wieńcowa i przerost mięśnia sercowego występowały z podobną częstością u chorych na cukrzycę 
i u osób bez cukrzycy.
4 Aterogenna dyslipidemia częściej występowała w populacji chorych na cukrzycę.
Słowa kluczowe: cukrzyca, nadciśnienie tętnicze, zawał serca, niewydolność serca, przerost mięśnia sercowego
(Folia Cardiologica 2014; 9, 1: 10–16)
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Komentarz
Makronaczyniowe powikłania cukrzycy — wyzwanie „multidyscyplinarne”, ważne informacje 
praktyczne
Przedstawiony Państwu artykuł dotyczy bardzo ważnego z praktycznego punktu widzenia 
zagadnienia — charakterystyki klinicznej pacjentów chorujących na cukrzycę, hospitalizo-
wanych na oddziale kardiologicznym w porównaniu z pacjentami bez cukrzycy. Ponadto 
u wszystkich osób z analizowanej grupy występowało nadciśnienie tętnicze.
Badanie ma charakter analizy retrospektywnej; jest oparte na dużej populacji (2513 
osób, w tym 637 chorych na cukrzycę). Jego wyniki są zgodne z wcześniej publikowanymi 
danymi z piśmiennictwa: chorzy na cukrzycę w większym odsetku przebyli zawał serca, 
częściej występowały u nich cechy niewydolności krążenia, niższa była u nich frakcja 
wyrzutowa, częściej występowały zaburzenia rytmu serca pod postacią migotania przed-
sionków. Częstsze były także zaburzenia lipidogramu pod postacią hipertriglicerydemii 
i obniżonego stężenia cholesterolu frakcji HDL oraz niższy był wskaźnik filtracji kłębusz-
kowej (GFR, glomerular filtration rate).
Problem ryzyka powikłań sercowo-naczyniowych jest kluczowy z punktu widzenia terapii cukrzycy. Powikłania makro-
naczyniowe są główną przyczyną nadumieralności pacjentów z cukrzycą typu 2; dane z piśmiennictwa na ten temat są 
szeroko cytowane w omawianej pracy. W tym kontekście chciałbym zwrócić uwagę Czytelnika na praktyczne znaczenie 
wyników uzyskanych przez autorów komentowanego artykułu, potwierdzających niekorzystne trendy chorobowości 
sercowo-naczyniowej u chorych na cukrzycę w populacji polskiej.
Zgodnie z wytycznymi Polskiego Towarzystwa Diabetologicznego (PTD) cele glikemiczne leczenia cukrzycy, intensyw-
ność terapii, powinny zależeć właśnie między innymi od obecności powikłań makronaczyniowych [1]. O ile celem lecze-
with and without prior myocardial infarction. N. Engl. J. Med. 1998; 
339: 229–234.
7. Tatoń J., Czech A., Krzemińska-Pakuła M. et al. Rekomendacje pre-
wencji, diagnostyki i leczenia chorób układu sercowo-naczyniowego 
u osób z cukrzycą. Przegląd Kardiodiabetologiczny 2008; 3: 85–206.
8. Kannel W., McGee D. Diabetes and cardiovascular risk factors: the 
Framingham study. Circulation 1979; 59: 8–13.
9. Kowalska I., Prokop J., Bachórzewska-Gajewska H. et al. Disturbances 
of glucose metabolism in men referred for coronary arteriography. 
Postload glycemia as predictor for coronary atherosclerosis. Diabetes 
Care 2001; 24: 897–901.
10. Lewczuk A., Hirnle T., Sobkowicz B. et al. Choroba wieńcowa i zawał 
serca u pacjenta z zaburzeniami gospodarki węglowodanowej. Przegl. 
Kardiodiabetol. 2008; 3: 285–295.
11. Nichols G., Reinier K., Chugh S. Independent contribiution of diabetes 
to increased prevalence and incidence of atrial fibrilation. Diabetes 
Care 2009; 32: 1851–1856.
12. Huxley R., Lopez F., Folsom A. et al. Absolute and attributable risks 
of atrial fibrillation in relation to optimal and borderline risk factors. 
Circulation 2011; 123: 1501–1508.
13. Camm J., Lip G., De Caterina R. et al. Wytyczne ESC dotyczące postę-
powania w migotaniu przedsionków na 2012 rok. Kardiol. Pol. 2012; 
70: 197–234.
14. Fein S., Sonnenblick E. Diabetic cardiomyopathy. Cardiovasc. Dis. 
1985; 27: 255–270.
15. Kannel W., Hjortland M., Castelli W. Role of diabetes in congestive 
heart failure: the Framingham study. Am. J. Cardiol. 1974; 34: 
29–34.
16. Bertoni A., Hundley W., Massing W. i wsp. Heart failure prevalence, 
incidence and mortality in the elderly with diabetes. Diabetes Care 
2004; 27:699–703.
17. Betoni A., Tsai A., Kasper E. et al. Diabetes and idiopathic cardiomy-
opathy. A nationwide case-control study. Diabetes Care 2003; 26: 
2791–2795.
18. Bella J., Devereux R., Roman M. et al. Separate and joint effects of 
systemic hypertension and diabetes mellitus on left ventricular stru-
cture and function in American Indians (the Strong Heart Study). Am. 
J. Cardiol. 2001; 87: 1260–1265.
19. Kuperstein R., Hanly P., Niroumand M. et al. Importance of age and 
obesity on the relations between diabetes and left ventricular mass. 
J. Am. Coll. Cardiol. 2001; 37: 1957–1962.
20. Rubiec-Niemirowska A., Czech A. Dyslipidemia cukrzycowa — znacze-
nie kliniczne i leczenie. Przew. Lek. 2009; 2: 61–67.
21. Bakris G., Weir M., Shanifar S. et al. Effects of blood pressure level on 
progression of diabetic nephropathy: results from the RENAAL study. 
Arch. Intern. Med. 2003; 163: 1555–1565.
17www.fc.viamedica.pl
Tomasz Klupa, Komentarz
nia u większości pacjentów będzie uzyskanie wartości hemoglobiny glikowanej (HbA1c) poniżej 7% (< 53 mmol/mol), 
to u znacznej części chorych, których dotyczyło omawiane badanie (pacjenci w wieku > 70 lat z wieloletnią cukrzycą 
i współistniejącymi istotnymi powikłaniami o charakterze makroangiopatii, takimi jak przebyty zawał serca i/lub udar 
mózgu), celem terapii będzie uzyskanie odsetka HbA1c poniżej 8% (64 mmol/mol). Taka wartość HbA1c oznacza średnie 
glikemie na poziomie 183 mg/dL (95-proc. przedział ufności [CI, confidence interval]: 147–217), czyli 10,2 mmol/l 
(95% CI: 8,1–12,1 mmol/l). Zbyt intensywne leczenie glikemii w tej grupie chorych, szczególnie narażanie na hipoglike-
mie, może stanowić dla nich duże zagrożenie [2]. Zatem w przypadku znacznego odsetka pacjentów hospitalizowanych 
na oddziałach kardiologicznych za zadowalające należy uznać osiągnięcie stosunkowo liberalnych celów leczenia.
Powikłania naczyniowe są również ważne dla wyboru leku hipoglikemizującego. Niewydolność krążenia będzie prze-
ciwwskazaniem do leczenia pioglitazonem [3], ostrożnie należy stosować saksagliptynę [4]. Po wykluczeniu przeciw-
wskazań terapią z wyboru u większości pacjentów z cukrzycą typu 2 i podwyższonym ryzykiem sercowo-naczyniowym 
pozostaje metformina [5]. Ogólnie bezpieczne wydają się też w tym przypadku leki działające w oparciu o oś inkre-
tynową [4, 6]. Niewydolność nerek, z kolei, może wymagać odstawienia większości pochodnych sulfonylomocznika, 
zmniejszenia dawki bądź odstawienia metforminy; bezpieczne będą w tym przypadku tiazolidynediony bądź niektóre 
inhibitory dipeptydylopeptydazy IV (DPP-IV), takie jak linagliptyna [1, 5].
Jeżeli chodzi o hipertriglicerydemię u pacjentów z cukrzycą, to pamiętajmy o tym, że w zdecydowanej większości przy-
padków jest to zjawisko wtórne do hiperglikemii — normalizacja glikemii prowadzi do obniżenia hipertriglicerydemii. 
W leczeniu hipertriglicerydemii ważne jest także zmniejszenie nadwagi, ograniczenie spożycia alkoholu, zmniejszenie 
spożycia mono- i dwusacharydów (redukcja spożycia fruktozy), ograniczenie spożycia tłuszczów nasyconych, włączenie 
do diety tłuszczów jednonienasyconych, redukcja spożycia węglowodanów [1]. Dlatego niezmiernie rzadko powinniśmy 
u chorych na cukrzycę sięgać po celowaną na triglicerydy farmakoterapię (fibrat) w monoterapii. U wszystkich chorych 
na cukrzycę i obciążonych podwyższonym ryzykiem sercowo-naczyniowym istnieją wskazania do leczenia statynami; 
dopiero wówczas sięgamy po terapię skojarzoną z fibratem, gdy nie osiągamy zakładanych celów lipemicznych w mono-
terapii statyną [1]. Zgodnie z zaleceniami PTD u chorych na cukrzycę ze współistniejącą hipertriglicerydemią większą 
lub równą 2 mmol/l (≥ 177 mg/dl), utrzymującą się po osiągnięciu docelowego stężenia cholesterolu frakcji LDL za 
pomocą statyn, należy rozważyć zwiększenie dawki statyn, aby obniżyć stężenie cholesterolu nie-HDL, który stanowi 
wtórny cel leczenia. W uzasadnionych przypadkach należy rozważyć leczenie skojarzone z fibratem lub pochodnymi 
kwasu nikotynowego [1].
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